Related Experiment Videos
Arotinoid-ethylester. Effectiveness in refractory cutaneous T-cell lymphoma
1Department of Dermatology, University of Hamburg, FRG.
Cancer
|September 15, 1988
Summary
A new retinoid, arotinoid-ethylester, showed promise in treating advanced cutaneous T-cell lymphoma (CTCL). Three of six patients achieved objective clinical responses, including one complete remission lasting over two years.
Area of Science:
- Dermatology
- Oncology
- Pharmacology
Background:
- Cutaneous T-cell lymphoma (CTCL) is a group of malignant diseases affecting the skin.
- Refractory CTCL cases often require novel therapeutic strategies.
- Retinoids possess antiproliferative properties with potential anti-cancer effects.
Purpose of the Study:
- To evaluate the efficacy and safety of arotinoid-ethylester in patients with refractory advanced CTCL.
- To assess the clinical response and duration of remission.
- To investigate the histopathological changes in skin biopsies following treatment.
Main Methods:
- A Phase I/II study involving six patients with refractory CTCL (Stages IB to IVA).
- Treatment administered with a new polyaromatic retinoid, arotinoid-ethylester (Ro 13-6298).
- Clinical response assessment, duration of remission tracking, and skin biopsy analysis at 4 weeks.
Main Results:
- Objective clinical response observed in 3 of 6 patients (1 complete remission, 2 partial remissions).
- Complete remission ongoing for 102 weeks; mean partial remission duration of 43 weeks.
- Histopathological examination showed clearance of mononuclear cell infiltration in 3 of 4 patients.
Conclusions:
- Arotinoid-ethylester demonstrates a promising therapeutic approach for refractory CTCL.
- The drug exhibited significant antiproliferative activity and clinical efficacy.
- Further investigation in larger cohorts is warranted to confirm these findings.